Startup Deep Dive : Thyrocare Technologies — the listed lab founder who sold to a startup and lost on the reinvestment

Thyrocare Technologies is valued at roughly ₹8,902 crore ($927 million) on the stock exchanges today, yet the man who built it from a ₹1-lakh provident-fund withdrawal no longer runs it and does not sit on its board. Dr A. Velumani turned a single-disease testing lab into only the second diagnostics company to list on India’s stock exchanges, then in June 2021 sold control to a loss-making online pharmacy startup that had never operated a single laboratory of its own.

That contradiction — a listed, profitable, three-decade-old company handed to a cash-burning startup — is the spine of this piece. It also explains why Thyrocare’s stock now carries a risk that has nothing to do with blood tests: a pledge on its promoter’s shares, tied to the debt of a parent company whose own valuation has been marked down by outside investors. Along the way there is a founder who reinvested his exit money into that same startup and says he lost ₹1,400 crore doing it, two rounds of regulatory bans during the one event that should have been Thyrocare’s biggest opportunity, and a business that still runs on a model most of its wellness-package customers never see: hospitals and doctors, not walk-in patients, generate roughly three-quarters of its revenue.

Quick facts

What they do

Thyrocare runs a centralised laboratory business: it does not chase patients through owned clinics the way a hospital chain does, it processes blood, urine and other samples sent in by a network of franchised collection points, hospitals, local pathology labs and individual doctors, then returns a report. Its original and still-largest customer base is other healthcare providers who need reliable, cheap, high-volume test processing rather than a diagnostics brand of their own. Alongside that referral business it sells directly to consumers through preventive health-checkup packages branded Aarogyam, which bundle anywhere from a handful of tests to over a hundred into a single price. The company says it now offers more than 900 individual tests and nearly 300 profiles, including 43 Aarogyam wellness packages, as per its own investor disclosures.

• Core customer base: hospitals, clinics, individual doctors and local pathology labs that outsource testing rather than run their own equipment.
• Consumer layer: preventive health packages under the Aarogyam brand, sold online and through franchise outlets, priced from roughly ₹799 for a basic panel to ₹7,999 for a comprehensive one (Thyrocare and reseller pricing pages, 2026).
• Geographic footprint: headquartered in Navi Mumbai with processing capacity across India and stated presence in Nepal, Bangladesh and parts of the Middle East (company disclosures, cited via Wikipedia, 2026).

The origin

Velumani spent 14 years at the Bhabha Atomic Research Centre, first as a laboratory assistant and later as a scientist, working with radioimmunoassay techniques used to measure thyroid hormones. He watched how expensive and inconsistent thyroid testing was for ordinary Indian patients at the time, most of whom had no reliable, affordable way to get tested at all. In 1995 he left the security of a government job, and in 1996 used roughly ₹1 lakh drawn from his provident fund to rent a small lab space in Byculla, Mumbai. His wife, Sumathi, left her job at the State Bank of India to become the company’s first employee.

The founding bet was narrow by design. Rather than offering a broad diagnostics menu from day one, Thyrocare built its entire lab and its entire business model around one test category, thyroid profiles, running them at a volume and cost per test that no single hospital lab could match. That volume-first, one-category focus was the founding insight: centralise everything expensive (equipment, reagents, quality control) in one place, and let a distributed network of collection partners feed it samples. Only once that hub-and-spoke model proved itself on thyroid testing did the company widen into the broader preventive and diagnostic-testing catalogue it runs today.

The struggle years

The model that made Thyrocare efficient also made it fragile at the edges, and two episodes exposed that in public. The first was internal and governance-driven. In September 2019, Thyrocare’s own audit committee reviewed and rejected an offer from Velumani, then still chairman, managing director and CEO, to personally buy back Nueclear Healthcare, the company’s wholly owned imaging and radiology subsidiary, from the listed entity. The committee’s stated reasoning, reported by Business Standard on 23 September 2019, was that the subsidiary’s long payback period meant the deal did not serve minority shareholders, and that pursuing it risked diverting the founder’s own attention from the core business. A related-party proposal from the company’s own founder being turned down by its own board is not the kind of setback a growth story usually advertises, but it happened in the open, on stock-exchange disclosure.

The second came at the worst possible moment: the one event that should have been an unambiguous windfall for a diagnostics company. As COVID-19 testing volumes exploded in 2020, Thyrocare scaled from roughly 200 tests a day in March to about 40,000 a day within months, and it went on to complete more than a million COVID-related tests by the end of that year, according to its own investor disclosures cited in market reports. But quality-control problems came with that speed. Mumbai’s civic body issued a show-cause notice and a testing suspension in April 2020 over incomplete or incorrect patient information in Thyrocare’s COVID reports; Panvel’s municipal corporation ordered it to stop testing in May 2020 over false-positive results; Navi Mumbai’s civic body sought cancellation of its registration in June 2020 after report discrepancies were linked to a patient death; Thane banned the company the same month for false positives; and a Pune facility was barred in July 2020 for the same reason, as reported by Hindustan Times and Business Standard through 2020. Four separate municipal bodies suspending or banning the same diagnostics company inside four months, during the single biggest demand spike in its history, is not a footnote — it is the clearest evidence that the centralised, high-volume model has a real quality-control ceiling when it is pushed hard and fast.

The turning point

On 26 June 2021, API Holdings, the parent company of online pharmacy PharmEasy, agreed to acquire a 66.1% controlling stake in Thyrocare from Velumani and the promoter group for ₹4,546 crore, a deal TechCrunch valued at roughly $613.5 million at the prevailing exchange rate, with an additional open-offer component for public shareholders taking the total transaction size past ₹6,300 crore, as reported by ETV Bharat and TechCrunch on the day the deal was announced. It made Thyrocare the first listed Indian company to be acquired by a venture-backed startup, and it ended Velumani’s 25-year run at the company he had built from a rented lab. He signed his resignation the same day he signed the share purchase agreement.

What happened on the other side of that transaction is the part most coverage of the deal leaves out. Velumani has since said, in comments reported by Forbes India and repeated across Indian business media in 2024, that he reinvested roughly ₹1,500 crore of his exit proceeds back into PharmEasy itself, taking a stake of around 5% in the very company that had just bought him out, hoping to ride its planned public listing. That listing never happened at the valuation PharmEasy had been chasing: independent fund manager Janus Henderson marked its own holding in PharmEasy down to imply a company valuation of about $2.8 billion in 2023, roughly half of what PharmEasy had been valued at in 2021. Velumani has publicly said he lost roughly ₹1,400 crore on that reinvestment, calling his own decision “greedy” in a widely reported 2024 interview. A founder who correctly priced his exit ended up mispricing his next bet by almost the same amount he had just been paid.

The money behind it

Thyrocare’s capital history looks unlike most startup deep dives in this series: it was bootstrapped for two decades, went public rather than raising private venture rounds, and its most consequential “backer” turned out to be its acquirer.

• 1996 seed capital: roughly ₹1 lakh from Velumani’s own provident fund, no institutional investors (The Better India, 2020s profile; corroborated across founder interviews).
• April-May 2016 IPO: Thyrocare raised up to ₹479-480 crore in a main-board IPO priced at ₹446 a share, including ₹144 crore from 15 anchor investors ahead of the issue; the offer was subscribed 73.55 times by close, per Business Standard, 30 April 2016. Shares listed on the NSE and BSE on 9 May 2016.
• June 2021 change of control: API Holdings (PharmEasy’s parent) bought Velumani’s 66.1% promoter stake for ₹4,546 crore, with Docon Technologies, an API Holdings subsidiary, becoming the new promoter entity, as reported by TechCrunch and ETV Bharat, 25-26 June 2021.
• Current ownership: Docon Technologies/API Holdings held roughly 60.9% as of mid-2026 before releasing a partial share pledge in August 2026 that took the encumbered promoter stake down toward 49.9%, and separately sold about a 10% stake in Thyrocare for roughly ₹668 crore reported in late 2025, part of API Holdings’ broader deleveraging (Scanx and Unlistedzone/Planify reporting, 2025-2026).

How it makes money

Strip away the consumer-facing wellness-package marketing and Thyrocare is, at its core, a high-volume, low-unit-cost testing factory that sells processing capacity to other healthcare providers.

• Money in: per-test or per-package fees, charged either to a franchisee/aggregator who has already collected a sample from a hospital or referring doctor, or directly to a consumer buying an Aarogyam package.
• Channel mix: business-to-business referral volume (hospitals, clinics, doctors, local labs routing samples through Thyrocare’s franchise network) contributes roughly 77% of revenue, with direct consumer wellness sales making up the rest, according to brokerage analysis of the company’s disclosures (TradeJini, 2026).
• Costs out: reagents and lab consumables are the largest single cost line, followed by the logistics of moving samples from thousands of collection points into a small number of centralised processing labs (one Central Processing Laboratory, four Zonal Processing Labs and 15 Regional Processing Labs, per company investor calls).
• Where the margin sits: in volume, not price. A single thyroid or wellness test carries a thin absolute margin, but running it through a centralised, largely automated lab at a scale of roughly 210 million tests in FY26 (up 23% year-on-year, per company results) is what turns thin unit economics into a 28%-plus EBITDA margin.
• What people get wrong: the Aarogyam advertising makes Thyrocare look like a consumer health-checkup brand competing for walk-in customers. Most of its volume actually comes from the unglamorous B2B side: franchisees, aggregators and referring doctors who never appear in the marketing.

The numbers

Thyrocare’s revenue dipped as pandemic-era testing volumes faded, then recovered on the back of a rebuilding wellness and chronic-disease testing business.

• FY23 revenue of ₹527 crore was the post-COVID trough, down from a pandemic-inflated FY22 base, as testing-related demand normalised (Screener.in compilation of audited consolidated financials, 2026).
• FY25 was the company’s highest annual revenue at that point, ₹687 crore, with EBITDA margin recovering to about 28% from roughly 23% in FY23 (company results commentary, 2025).
• FY26 revenue reached ₹829 crore, up 21% year-on-year, with full-year PAT of ₹162.85 crore, up 81% year-on-year, and test volumes of 209.6 million, up 23% (Thyrocare Q4 FY26 results, reported by EquityBulls and Medical Buyer, April-May 2026).
• Q4 FY26 alone delivered ₹223.95 crore of revenue (up 20% year-on-year) and ₹48.70 crore of PAT (up 128% year-on-year), the fastest quarterly profit growth in the four-year set (EquityBulls, April 2026).

Where the money comes from

Two splits matter for Thyrocare: how revenue divides between channels, and how it divides between test categories. Both point the same way — toward the unglamorous, high-volume core rather than the branded consumer product.

• By channel: business-to-business referral volume (hospitals, doctors, local labs, franchise aggregators) accounts for an estimated 77% of revenue, with direct-to-consumer wellness sales making up the remainder (TradeJini analyst note, 2026).
• By service line: diagnostic testing services made up about 92% of FY25 revenue, with the balance coming from other operations including radiology/imaging (company disclosures cited in market commentary, 2025-2026).
• By product: the Aarogyam wellness-package range contributes around 36% of pathology sales on its own, making it the single largest product line even though it sits inside a business that is majority B2B by channel (TradeJini analyst note, 2026).
• The surprise: a company whose public brand is built almost entirely around consumer-facing preventive-health packages still earns most of its money from hospitals and doctors sending it samples in bulk, not from people booking a checkup online.

The risks

• Parent-company and pledge risk: Thyrocare’s controlling shareholder, Docon Technologies, is a subsidiary of API Holdings/PharmEasy, and had pledged the bulk of its Thyrocare shares to secure API Holdings’ own debentures. Any missed payment, credit downgrade or liquidity event at the parent could let debenture holders invoke that pledge and sell Thyrocare shares in the open market, a mechanism that has already forced partial pledge releases and stake sales in 2025-2026 (Unlistedzone/Planify and Scanx reporting, 2025-2026). Since Janus Henderson’s mark-down implied a roughly $2.8 billion valuation for PharmEasy in 2023, half its earlier level, the parent’s own financial health is not guaranteed.
• Quality-control and regulatory risk: the 2020 sequence of municipal bans across Mumbai, Panvel, Navi Mumbai, Thane and Pune showed that Thyrocare’s centralised, high-throughput model can produce false positives and reporting errors when volumes spike quickly, each incident carrying the risk of a city-level suspension that shuts off revenue in that market overnight (Hindustan Times and Business Standard reporting, 2020).
• Franchisee dependence and price competition: because roughly three-quarters of revenue flows through franchised collection partners and B2B referrals rather than owned outlets, Thyrocare’s volumes are exposed to how aggressively rivals such as Dr Lal PathLabs and Metropolis Healthcare price their own referral commissions and wellness packages, a competitive dynamic that compresses per-test realisation even as overall test volumes keep growing.

The takeaway

Thyrocare’s real lesson is not about diagnostics at all. It is that the skill that builds a category is not automatically the skill that knows what to do with the money once you have been paid for it. Velumani correctly read a gap in Indian healthcare in 1996, built a genuinely differentiated low-cost, high-volume model around it, survived a public governance dispute and a public quality-control crisis, and negotiated an exit that valued his company at multiples of what he had put in. Then, by his own account, he handed a large share of those proceeds straight back into the very acquirer that had just bought him out, on the strength of a listing that never arrived at the price he expected, and it cost him nearly as much as he had just been paid. Building the thing and knowing what to do after you have sold it are two different disciplines, and success at one says nothing about competence at the other.

Frequently asked questions

Is Thyrocare still owned by its founder, Dr A. Velumani?

No. Velumani sold his 66.1% controlling stake to API Holdings, the parent of PharmEasy, for ₹4,546 crore in June 2021 and resigned from the company the same day, as reported by TechCrunch and ETV Bharat on 25-26 June 2021.

What kind of tests does Thyrocare actually run?

Thyrocare offers more than 900 individual diagnostic tests and close to 300 test profiles, spanning routine pathology through to preventive wellness packages sold under its Aarogyam brand, processed centrally through a hub-and-spoke laboratory network rather than at each collection point.

Is Thyrocare profitable?

Yes. The company reported a consolidated net profit of ₹163 crore on revenue of ₹829 crore for FY26 (year to March 2026), up 81% and 21% year-on-year respectively, according to its results reported by EquityBulls and Medical Buyer in April-May 2026.

Who controls Thyrocare now?

Docon Technologies, a subsidiary of API Holdings (PharmEasy’s parent), is the controlling promoter, holding roughly 60.9% of the company as of mid-2026 before a partial pledge release in August 2026 and a reported 10% stake sale in late 2025 reduced its encumbered and total holding.

Why does Thyrocare’s share price carry PharmEasy-related risk?

Because a large portion of the promoter’s Thyrocare shares were pledged to secure debt raised by API Holdings, PharmEasy’s parent. If API Holdings were to miss a payment or face a credit event, lenders could sell those pledged shares in the open market, which is a risk specific to Thyrocare’s ownership structure rather than its underlying diagnostics business.

Sources

Figures are as of September 2026. Currency converted at $1 ≈ ₹96.0 as of 18 September 2026 (Trading Economics).

• TechCrunch, “PharmEasy to acquire majority stake in listed firm Thyrocare for over $600 million,” June 2021
• ETV Bharat, “PharmEasy to acquire Thyrocare in Rs 4,546 crore deal,” June 2021
• Business Standard, “Thyrocare’s Rs 479 cr IPO oversubscribed 2.24 times on Day 2,” April 2016
• Business Standard, “Thyrocare IPO subscribed 73 times, gets huge response on closing day,” April 2016
• Business Standard, “Thyrocare slips after board rejects founder Velumani’s offer,” September 2019
• Hindustan Times / Business Standard, reporting on municipal COVID-19 testing bans on Thyrocare, April-July 2020
• Forbes India, “From zero debt unicorn to successful exit: Arokiaswamy Velumani’s journey with Thyrocare Technologies and life since,” 2024
• Business Standard, “US investor Janus Henderson marks down PharmEasy’s valuation by half to $2.8 bn,” May 2023
• EquityBulls, “Thyrocare Reports Robust Q4FY26 Results – Revenue Up 20%, PAT Up 128%,” April-May 2026
• Medical Buyer, “Thyrocare revenue up 20%, PAT 128% in Q4FY26,” 2026
• Screener.in, compiled consolidated financial statements of Thyrocare Technologies Ltd, accessed September 2026
• TradeJini, “Thyrocare Technologies: Analysis of Business Model, Growth Drivers & Financial Outlook (Q2 FY26),” 2026
• Unlistedzone / Planify, reporting on Docon Technologies’ share pledge on Thyrocare and API Holdings debentures, 2025-2026
• Scanx, “Thyrocare promoter Docon releases pledge on shares after debt repayment,” 2026
• Wikipedia, “Thyrocare,” accessed September 2026, cross-checked against primary news reporting cited above
• The Better India, founder profile of Dr A. Velumani, cross-checked against multiple founder interviews

Found an error? Write to us and we’ll correct it in the open, dated, on the piece.